查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
年齡相關性黃斑變性市場規模、份額和趨勢分析報告：按產品（Eilea、Lucentis、Beov）、疾病類型（濕性 AMD、乾性 AMD）、分銷渠道、地區、細分市場、預測 2022-2030
市場調查報告書
商品編碼
1122210

年齡相關性黃斑變性市場規模、份額和趨勢分析報告：按產品（Eilea、Lucentis、Beov）、疾病類型（濕性 AMD、乾性 AMD）、分銷渠道、地區、細分市場、預測 2022-2030

Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

年齡相關性黃斑變性市場增長和趨勢

根據 Grand View Research, Inc 的一項新研究，到 2030 年，全球與年齡相關的黃斑變性市場預計將達到 179.9 億美元。預計從 2022 年到 2030 年，其複合年增長率為 6.9%。這種增長的背後是對新產品開發、產品發布、年齡相關性黃斑變性 (AMD) 患病率上升以及人口老齡化的高額研發投資。

在濕性（滲出性）和乾性（乾性）年齡相關性黃斑變性中，乾性 AMD 是較常見的眼部疾病，85-90% 的病例因視網膜玻璃膜疣過多而導致視力受損。根據美國國家眼科研究所的統計，到 2020 年，美國進行性年齡相關性黃斑變性的患病率約為 300 萬。

目前還沒有批准用於治療乾性年齡相關性黃斑變性的藥物。這為市場參與者提供了解決乾性 AMD 患者未滿足的醫療需求的機會。然而，對於濕性 AMD，抗 VEGF 藥物用於治療和預防病情進一步惡化。

然而，在濕性 AMD 的情況下，使用抗 VEGF 藥物進行治療，但由於頻繁的醫院就診和較短的給藥間隔，患者傾向於在治療完成前停止治療。主要公司正在研究和開髮長效抗 VEGF 製劑以滿足不斷增長的需求。2020 年 2 月，Novartis AG獲得歐盟委員會批准其黃斑變性治療藥物 Beov 用於治療年齡相關性黃斑變性。這種藥物是一種長效藥物，第一年每隔 12 週給藥一次。

2022 年 1 月，F. Hoffmann-La Roche Ltd. 的候選藥物 Bavismo (falisimab) 將在美國獲得批准，用於治療年齡相關性黃斑變性。獲得FDA批准。此外，2021年10月，Roche's Susvimo獲得FDA批准，預計2022年進入美國。這是一種專為 LUCENTIS 給藥而設計的可再填充植入物，可再填充壽命為 6 個月。所有這些因素預計將在預測期內推動市場增長。

EYLEA 在美國的專利到期日為 2023 年，在歐洲為 2025 年，具體取決於幾個專利類別。Lucentis (F. Hoffmann La Roche Ltd.) 於 2020 年 6 月在美國失去專利，並將於 2022 年在歐洲失去專利保護。因此，生物仿製藥製造商正在利用這個機會進入 AMD 市場。例如，2021 年 10 月，Formycon AG 和 Bioeq AG 獲得了美國 FDA 對其 Lucentis 生物仿製藥 BLA 的認可。PDUFA 審查申請的截止日期定於 2022 年 8 月。所有這些因素都可能阻礙預測期內的市場增長。

年齡相關性黃斑變性市場報告亮點

按產品劃分，由於市場滲透率高和專利保護，Eylea 在 2021 年佔據了最大的收入份額。Biob由於其專利保護和出色的干燥效果，預計在預測期內增長最快

按疾病類型劃分，由於 Eylea、Lucentis 和 Beovu 等領先的抗 VEGF 產品的上市，濕性 AMD 將在 2021 年佔據最大份額。

北美將在 2021 年佔據最大的市場份額，預計在預測期內將繼續佔據主導地位，因為有更好的報銷設施和大量採用新的老年性黃斑變性藥物進行治療

通過分銷渠道，專業藥房預計在預測期內增長最快，因為製造商正在與他們合作推銷他們的產品。

目錄

第一章 調查方法和範圍

  • 市場細分
    • 估計/預測時間表
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 第一次調查的內容
    • 主要信息列表
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法一：商品流動方法
      • 方法 2：使用自下而上的方法進行國別市場估算
  • 全球市場：複合年增長率計算
  • 調查假設
  • 二級信息列表
  • 縮略語表
  • 目的

第二章執行摘要

  • 市場概況

第三章市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
  • 監管框架
  • 繪製滲透率和增長前景
  • 按階段進行管道分析
    • 主要即將推出的產品
  • 市場動態
    • 市場驅動力分析
    • 市場約束分析
  • PESTEL 分析
  • 市場化管理途徑的質量分析
    • 在玻璃體內
    • 其他
  • 流行病學分析
  • 未滿足需求分析

第 4 章全球年齡相關性黃斑變性市場細分分析，按產品，2018-2030 年（百萬美元），患者份額（%）

  • 全球年齡相關性黃斑變性市場：產品變異分析
  • Eylea
  • Lucentis
  • Beovu
  • 其他

5. 2018-2030 年全球年齡相關性黃斑變性市場細分分析，按疾病類型（百萬美元）

  • 全球年齡相關性黃斑變性市場：疾病類型的變異分析
  • 乾性 AMD
  • 濕性 AMD

6. 2018-2030 年全球年齡相關性黃斑變性市場細分分析，按分銷渠道（百萬美元）

  • 全球年齡相關性黃斑變性市場：分銷渠道的變化分析
  • 醫院藥房
  • 專業藥房
  • 網上藥店

7. 年齡相關性黃斑變性市場：細分分析，按地區，2018-2030 年（百萬美元）

  • 年齡相關性黃斑變性市場：按地區分列的變化分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 意大利
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中東和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國

8 全球年齡相關性黃斑變性市場：競爭分析

  • 主要市場參與者的最新發展和影響分析
    • 重大交易和戰略聯盟分析
      • 新產品發布
      • 併購
      • 夥伴關係和合同
  • 公司分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 熱圖分析
  • 公司市場分析
  • 供應商情況
    • 主要經銷商及渠道合作夥伴名單
    • 潛在最終用戶列表
    • 2021 年主要參與者的市場份額分析
  • 2021年公司市場份額
    • 競爭儀錶盤分析
  • 民營企業
    • 主要初創企業名單
    • 區域網絡圖
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Novartis AG
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Bayer AG
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Pfizer Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Bausch Health Companies Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Regeneron Pharmaceuticals Inc.
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • Amgen Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
    • Biogen
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • Samsung Bioepis
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68039-971-3

Age-related Macular Degeneration Market Growth & Trends:

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2022 to 2030. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

  • By product, eylea accounted for the largest revenue share in 2021 owing to the higher market penetration and patent protection. Beovu is anticipated to be the fastest-growing segment over the forecast period due to patent protection and superior drying efficacy
  • By disease type, wet AMD held the largest share in 2021 owing to the availability of major anti-VEGF products including Eylea, Lucentis, and Beovu
  • North America held the largest market share in 2021 and is expected to dominate over the forecast period due to better reimbursement facilities and the high adoption of novel age-related macular degeneration drugs for the treatment
  • Based on distribution channel, specialty pharmacy is expected to be the fastest-growing segment during the forecast period owing to increasing collaboration of manufacturers with specialty pharmacies for distributing their products

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR'S internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
    • 1.3.6 List of primary sources
  • 1.4 Information or data analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country - wise market estimation using bottom - up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Abbreviations
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Regulatory framework
  • 3.3 Penetration and Growth Prospect Mapping
  • 3.4 Pipeline Analysis, by Phase
    • 3.4.1 Key upcoming products
  • 3.5 Market Dynamics
    • 3.5.1 Market driver analysis
    • 3.5.2 Market restraint analysis
  • 3.6 PESTEL Analysis
  • 3.7 Quality Analysis of the market based route of administration
    • 3.7.1 Intravitreal
    • 3.7.2 Others
  • 3.8 Epidemiology Analysis
  • 3.9 Unmet Need Analysis

Chapter 4 Global Age - Related Macular DegenerationMarket - Segment Analysis, By Product, 2018 - 2030 (USD Million), Patient Share (%)

  • 4.1 Global Age - Related Macular DegenerationMarket: Product Movement Analysis
  • 4.2 Eylea
    • 4.2.1 Eyleaage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
  • 4.3 Lucentis
    • 4.3.1 Lucentisage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
  • 4.4 Beovu
    • 4.4.1 Beovuage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
  • 4.5 Others
    • 4.5.1 Othersage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)

Chapter 5 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Disease Type, 2018 - 2030 (USD Million)

  • 5.1 Global Age - Related Macular DegenerationMarket: Disease Type Movement Analysis
  • 5.2 Dry AMD
    • 5.2.1 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Wet AMD
    • 5.3.1 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1 Global Age - Related Macular DegenerationMarket: Distribution Channel Movement Analysis
  • 6.2 Hospital Pharmacy
    • 6.2.1 Hospital Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Specialty Pharmacy
    • 6.3.1 Specialty Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Online Pharmacy
    • 6.4.1 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Age - Related Macular DegenerationMarket: Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 7.1 Age - Related Macular DegenerationMarket: Regional Movement Analysis
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Spain
      • 7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Italy
      • 7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 South Korea
      • 7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.3 Mexico
      • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.4 Argentina
      • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East & Africa
      • 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.2 South Africa
      • 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.3 Saudi Arabia
      • 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.5 United Arab Emirate
      • 7.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Global Age - Related Macular DegenerationMarket: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 Major deals & strategic alliances analysis
      • 8.1.1.1 New Product Launches
      • 8.1.1.2 Mergers and Acquisitions
      • 8.1.1.3 Partnerships & Agreements
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
    • 8.2.3 Emerging Players
    • 8.2.4 Heat Map Analysis
  • 8.3 Company Market Position Analysis
  • 8.4 Vendor Landscape
    • 8.4.1 List of Key Distributors and Channel Partners
    • 8.4.2 List of Potential End Users
    • 8.4.3 Key Company Market Share Analysis, 2021
  • 8.5 Company Market Share, 2021
    • 8.5.1 Competitive Dashboard Analysis
  • 8.6 Private Companies
    • 8.6.1 List of Key Emerging Companies
    • 8.6.2 Regional Network Map
  • 8.7 Company Profiles
    • 8.7.1 F. Hoffmann - La Roche Ltd.
      • 8.7.1.1 Company overview
      • 8.7.1.2 Financial performance
      • 8.7.1.3 Product benchmarking
      • 8.7.1.4 Strategic initiatives
    • 8.7.2 Novartis AG
      • 8.7.2.1 Company overview
      • 8.7.2.2 Financial performance
      • 8.7.2.3 Product benchmarking
      • 8.7.2.4 Strategic initiatives
    • 8.7.3 Bayer AG
      • 8.7.3.1 Company overview
      • 8.7.3.2 Financial performance
      • 8.7.3.3 Product benchmarking
      • 8.7.3.4 Strategic initiatives
    • 8.7.4 Pfizer Inc.
      • 8.7.4.1 Company overview
      • 8.7.4.2 Financial performance
      • 8.7.4.3 Product benchmarking
      • 8.7.4.4 Strategic initiatives
    • 8.7.5 Bausch Health Companies Inc.
      • 8.7.5.1 Company overview
      • 8.7.5.2 Financial performance
      • 8.7.5.3 Product benchmarking
      • 8.7.5.4 Strategic initiatives
    • 8.7.6 Regeneron Pharmaceuticals Inc.
      • 8.7.6.1 Company overview
      • 8.7.6.2 Product benchmarking
      • 8.7.6.3 Strategic initiatives
    • 8.7.7 Amgen Inc.
      • 8.7.7.1 Company overview
      • 8.7.7.2 Financial performance
      • 8.7.7.3 Product benchmarking
    • 8.7.8 Biogen
      • 8.7.8.1 Company overview
      • 8.7.8.2 Financial performance
      • 8.7.8.3 Product benchmarking
      • 8.7.8.4 Strategic initiatives
    • 8.7.9 Samsung Bioepis
      • 8.7.9.1 Company overview
      • 8.7.9.2 Financial performance
      • 8.7.9.3 Product benchmarking
      • 8.7.9.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Age-Related Macular DegenerationMarket, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 5 Global Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 6 GlobalAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 8 North America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 9 North America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 11 U.S. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 12 U.S.Age-Related Macular DegenerationMarket, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Canada Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 14 Canada Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 17 Europe Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 20 Germany Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 U.K. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 23 U.K. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 24 U.K.Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 26 France Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 29 Italy Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 30 ItalyAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 32 Spain Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 33 SpainAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 35 Asia Pacific Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Asia PacificAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Age-Related Macular DegenerationMarket, By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 38 Japan Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 39 JapanAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 China Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 41 China Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 42 China Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 India Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 44 India Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 45 India Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 South Korea Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 47 South Korea Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 48 South Korea Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Australia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 50 Australia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 51 Australia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Latin America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 53 Latin America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 54 Latin America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Brazil Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 56 Brazil Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 57 BrazilAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 Mexico Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 59 Mexico Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 60 MexicoAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Argentina Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 62 Argentina Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 63 ArgentinaAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Middle East & Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 65 Middle East & Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 66 Middle East & Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Saudi Arabia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 68 Saudi Arabia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 69 Saudi Arabia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 South Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 71 South Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 72 South Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 UAE Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 74 UAE Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 75 UAEAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Age-Related Macular Degenerationmarket segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Age-Related Macular Degenerationmarket snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Age related macular degenerationmarket driver impact
  • Fig. 14 Age related macular degenerationmarket restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's
  • Fig. 17 Strategy mapping
  • Fig. 18 Age-Related Macular Degenerationmarket: Product outlook and key takeaways
  • Fig. 19 Age-Related Macular Degenerationmarket: Product movement analysis & market share 2021 & 2030
  • Fig. 20 Eyleaage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million) (Patient Share in %)
  • Fig. 21 Lucentisage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
  • Fig. 22 Beovu age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
  • Fig. 23 Others age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
  • Fig. 24 Age-Related Macular Degenerationmarket: Disease type outlook and key takeaways
  • Fig. 25 Age-Related Macular Degenerationmarket: Disease Type movement analysis & market share 2021 & 2030
  • Fig. 26 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Age-Related Macular Degenerationmarket: Distribution channel movement analysis & market share 2021 & 2030
  • Fig. 29 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Specialty Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Opioids: Regional outlook and key takeaways
  • Fig. 33 Regional outlook, 2021 & 2030
  • Fig. 34 North America
  • Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S.
  • Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Canada
  • Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Europe
  • Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 U.K.
  • Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Germany
  • Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 France
  • Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Italy
  • Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific
  • Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Japan
  • Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • Fig. 56 China
  • Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 India
  • Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea
  • Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Australia
  • Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America
  • Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil
  • Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina
  • Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East & Africa
  • Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa
  • Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia
  • Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 UAE
  • Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Market differentiators
  • Fig. 81 Key company market share analysis, 2021
  • Fig. 82 Company market position analysis
  • Fig. 83 Competitive dashboard analysis
  • Fig. 84 Regional network map